Cytokine Release Syndrome (CRS) Is Not Required for CAR-T Cell Efficacy in Aggressive Large B-NHL

被引：0
|
作者：
Bhaskar, Shakthi [1 ]
Patel, Vivek [1 ]
Porter, David L. [2 ]
Schuster, Stephen J. [2 ]
Nastoupil, Loretta J. [3 ]
Perales, Miguel-Angel [4 ,5 ]
Tomas, Ana Alarcon [6 ,7 ]
Bishop, Michael R. [8 ]
McGuirk, Joseph P. [9 ]
Maziarz, Richard T. [10 ]
Chen, Andy [11 ]
Bachanova, Veronika [12 ]
Riedell, Peter A. [8 ]
Oluwole, Olalekan O. [1 ]
机构：
[1] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[2] Univ Penn, Abramson Canc Ctr, Blood & Marrow Transplant & Cellular Therapy Prog, Philadelphia, PA 19104 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA
[4] Mem Sloan Kettering Canc Ctr, Dept Med, Adult Bone Marrow Transplant Serv, Cellular Therapy Serv, 1275 York Ave, New York, NY 10021 USA
[5] Weill Cornell Med Coll, Dept Med, New York, NY USA
[6] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA
[7] Univ Murcia, PhD Program Signals Integrat & Modulat Biomed Cel, Murcia, Spain
[8] Univ Chicago, David & Etta Jonas Ctr Cellular Therapy, Chicago, IL 60637 USA
[9] Univ Kansas, Div Hematol Malignancies & Cellular Therapeut, Med Ctr, Kansas City, KS USA
[10] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR USA
[11] Oregon Hlth & Sci Univ, Ctr Hematol Malignancies, Knight Canc Inst, Portland, OR USA
[12] Univ Minnesota, Div Hematol Oncol & Transplantat, Minneapolis, MN USA
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-155886
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：10971 / 10973
页数：3
相关论文
共 50 条
  • [21] Retrospective Comparison of the Roles of Tocilizumab and Siltuximab in the Management of Toxicity in CAR-T Cell Therapy for Relapsed/Refractory B-NHL
    Liu, Rui
    Yang, Fan
    Ma, Lixia
    Guo, Yuelu
    Fu, Zhonghua
    Deng, Biping
    Chen, Chen
    Ke, Xiaoyan
    Hu, Kai
    BLOOD, 2024, 144 : 7247 - 7248
  • [22] Severe cases of local cytokine release syndrome (CRS); craniocervical edema soon after chimeric antigen T-cell (CAR-T) therapy
    Nakamura, Naokazu
    Jo, Tomoyasu
    Arai, Yasuyuki
    Kitawaki, Toshio
    Nishikori, Momoko
    Mizumoto, Chisaki
    Kanda, Junya
    Yamashita, Kouhei
    Nagao, Miki
    Takaori-Kondo, Akifumi
    OXFORD MEDICAL CASE REPORTS, 2025, 2025 (01):
  • [23] Tocilizumab Administration in CAR-T Cell Associated Cytokine Release Syndrome Induces Hypofibrinogenemia
    Perl, Markus
    Herfeld, Konstantin
    Harrer, Dennis
    Hoepting, Matthias
    Schweiger, Marina
    Sterz, Ulrich
    Knoedler, Leonard
    Hansmann, Leo
    Herr, Wolfgang
    Poeck, Hendrik
    Wolff, Daniel
    Edinger, Matthias
    Hart, Christina
    Fante, Matthias
    BLOOD, 2023, 142
  • [24] Nurses' roles in CAR-T therapy for B-cell malignancies and managing associated cytokine release syndrome
    Nwozichi, Chinomso
    Ogunmuyiwa, Ayodeji O.
    Ojewale, Margaret O.
    ASIA-PACIFIC JOURNAL OF ONCOLOGY NURSING, 2024, 11 (02)
  • [25] APOPTOTIC CELLS THERAPY FOR THE PREVENTION OF CYTOKINE RELEASE SYNDROME (CRS) IN CAR T-CELL THERAPY
    Mevorach, D.
    CYTOTHERAPY, 2017, 19 (05) : S10 - S10
  • [26] The impact of obesity and its related underlying diseases on cytokine release syndrome and the efficacy of CAR-T therapy in treating B-cell malignancies
    Mengyi Du
    Rosanna Tryphene Massounga Mayombo
    Jiachen Liu
    Yinqiang Zhang
    Danying Liao
    Yu Hu
    Heng Mei
    Annals of Hematology, 2025, 104 (3) : 1887 - 1895
  • [27] Metabolic tumor burden and cytokine release syndrome (CRS) in patients with diffuse large cell B lymphoma (DLCBL) treated with CTL019 chimeric antigen receptor -T-cell (CAR-T): preliminary experience
    Mantarro, C.
    Donegani, M.
    Bauckneht, M.
    Raffa, S.
    Chiola, S.
    Miceli, A. A.
    Lanfranchi, F.
    D'Amico, F.
    Sambuceti, G.
    Raiola, A.
    Ghiggi, C.
    Angelucci, E.
    Morbelli, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (SUPPL 1) : S540 - S540
  • [28] Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL
    Gauthier, Jordan
    Gazeau, Nicolas
    Hirayama, Alexandre, V
    Hill, Joshua A.
    Wu, Vicky
    Cearley, Aisling
    Perkins, Paula
    Kirk, Angela
    Shadman, Mazyar
    Chow, Victor A.
    Gopal, Ajay K.
    Dwinal, Alexandria Hodges
    Williamson, Staci
    Myers, Jessie
    Chen, Andy
    Nagle, Sarah
    Hayes-Lattin, Brandon
    Schachter, Levanto
    Maloney, David G.
    Turtle, Cameron J.
    Sorror, Mohamed L.
    Maziarz, Richard T.
    BLOOD, 2022, 139 (26) : 3722 - 3731
  • [29] A MODIFIED EASIX (M-EASIX) SCORE PREDICTS THE DEVELOPMENT OF GRADE 2-4 CRS IN PATIENTS WITH AGGRESSIVE B-NHL TREATED WITH ANTI CD19 CAR-T CELLS
    Galli, E.
    Di Rocco, A.
    Sora, F.
    Autore, F.
    Limongiello, M. A.
    Innocenti, I.
    Metafuni, E.
    Giammarco, S.
    La Rocca, U.
    Barberi, W.
    Pepe, S.
    Ansuinelli, M.
    Laurenti, L.
    Bacigalupo, A.
    Chiusolo, P.
    Iori, A.
    Martelli, M.
    Hohaus, S.
    Sica, S.
    HAEMATOLOGICA, 2022, 107 : 91 - 91
  • [30] Establishment of a Dynamic Ctdna Monitoring System to Predict the Prognosis of CAR-T Cell Therapy in R/R B-NHL Patients
    Zhou, Linghui
    Cheng, Tao
    Hu, Yongxian
    Huang, He
    BLOOD, 2023, 142
12345